Vivos Therapeutics (VVOS) on Wednesday announced receipt of a letter from Nasdaq stating that it currently complies with listing rules, requiring the company to maintain stockholders’ equity of at least $2.5 million.
CryptoAlerta — análise de criptomoedas e mercado em tempo real